Zeinhom MG, Aref HM, El-khawas H, et al. - The data indicate that regarding safety profile, ticagrelor was noninferior to aspirin. The results showed that ticagrelor had a better clinical outcome based on NIHSS and mRS in first-ever acute ischemic stroke patients who received it within 9 hours from symptom onset, leading to a shorter hospital stay compared with aspirin.

• Between May 2019 and September 2020, researchers performed an open-label, randomized prospective controlled clinical trial on patients who presented with their first-ever ischemic stroke and were recruited from the emergency department of Kafr el-sheik University Hospitals, Egypt.

• In this study, 84 patients received aspirin while ticagrelor was given to 85 patients.

• No significant difference was found between the 2 groups regarding the hemorrhagic and non-hemorrhagic complications.

• The findings revealed that individuals who received ticagrelor had a better outcome regarding NIHSS improvement at 2 days and 1 week or discharge and a favorable mRS score after 1 week or discharge and at 90-day follow-up.